Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin.
Uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists with fast off-rate (UFO) may represent promising drug candidates for various neurodegenerative disorders. In this study, we report that bis(propyl)-cognitin, a novel dimeric acetylcholinesterase inhibitor and gamma-aminobutyric acid subtype A receptor antagonist, is such an antagonist of NMDA receptors. In cultured rat hippocampal neurons, we demonstrated that bis(propyl)-cognitin voltage-dependently, selectively, and moderately inhibited NMDA-activated currents. The inhibitory effects of bis(propyl)-cognitin increased with the rise in NMDA and glycine concentrations. Kinetics analysis showed that the inhibition was of fast onset and offset with an off-rate time constant of 1.9 s. Molecular docking simulations showed moderate hydrophobic interaction between bis(propyl)-cognitin and the MK-801 binding region in the ion channel pore of the NMDA receptor. Bis(propyl)-cognitin was further found to compete with [(3)H]MK-801 with a K(i) value of 0.27 mum, and the mutation of NR1(N616R) significantly reduced its inhibitory potency. Under glutamate-mediated pathological conditions, bis(propyl)-cognitin, in contrast to bis(heptyl)-cognitin, prevented excitotoxicity with increasing effectiveness against escalating levels of glutamate and much more effectively protected against middle cerebral artery occlusion-induced brain damage than did memantine. More interestingly, under NMDA receptor-mediated physiological conditions, bis(propyl)-cognitin enhanced long-term potentiation in hippocampal slices, whereas MK-801 reduced and memantine did not alter this process. These results suggest that bis(propyl)-cognitin is a UFO antagonist of NMDA receptors with moderate affinity, which may provide a pathologically activated therapy for various neurodegenerative disorders associated with NMDA receptor dysregulation.
Luo
Jialie
J
Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, Hong Kong Polytechnic University, Hong Kong, China.
Li
Wenming
W
Zhao
Yuming
Y
Fu
Hongjun
H
Ma
Dik-Lung
DL
Tang
Jing
J
Li
Chaoying
C
Peoples
Robert W
RW
Li
Fushun
F
Wang
Qinwen
Q
Huang
Pingbo
P
Xia
Jun
J
Pang
Yuanping
Y
Han
Yifan
Y
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D019281:Dimerization; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008958:Models, Molecular; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D018408:Patch-Clamp Techniques; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000235:genetics; D013619:Tacrine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014162:Transfection; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; C000609450:bis(heptyl)cognitin; C551529:bis(propyl)cognitin; D013619:Tacrine; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Eur J Pharmacol. 1999 Jun 30;375(1-3):115-20
10443569
Science. 1992 Nov 27;258(5087):1498-501
1359647
J Pharmacol Exp Ther. 2002 Jul;302(1):163-73
12065713
Neuroreport. 2008 Dec 3;19(18):1809-13
18971795
J Neurosci. 1992 Nov;12(11):4427-36
1432103
Nat Rev Neurosci. 2007 Oct;8(10):803-8
17882256
J Med Chem. 2008 Feb 14;51(3):347-72
18181565
Neurosci Res. 2006 Jun;55(2):142-5
16616791
Trends Pharmacol Sci. 2005 Jan;26(1):27-35
15629202
Nat Rev Drug Discov. 2006 Feb;5(2):160-70
16424917
Curr Alzheimer Res. 2007 Sep;4(4):386-96
17908041
PLoS One. 2008 Aug 21;3(8):e3029
18716656
Bioorg Med Chem. 1999 Feb;7(2):351-7
10218828
N Engl J Med. 1994 Mar 3;330(9):613-22
7905600
J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74
15665416
Neuropharmacology. 2007 Feb;52(2):436-43
17056074
Cell Mol Life Sci. 2004 Mar;61(6):657-68
15052409
Neuroscientist. 2005 Feb;11(1):37-49
15632277
Br J Pharmacol. 1996 Feb;117(4):689-97
8646415
Biochem Soc Trans. 2004 Dec;32(Pt 6):1029-31
15506955
Mol Pharmacol. 2002 Mar;61(3):533-45
11854433
Stroke. 1986 May-Jun;17(3):472-6
3715945
J Biol Chem. 2005 May 6;280(18):18179-88
15710623
J Physiol. 1997 Feb 15;499 ( Pt 1):27-46
9061638
Neurochem Int. 2004 Oct;45(5):583-95
15234100
Neuropharmacology. 2006 Dec;51(7-8):1181-91
17011596
NeuroRx. 2004 Jan;1(1):101-10
15717010
Prague Med Rep. 2005;106(2):113-36
16315761
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3519-24
11248110
Neuroscientist. 2007 Dec;13(6):594-615
17911221
Neurotoxicology. 2008 Jan;29(1):101-8
17981335
Neuropharmacology. 2007 Nov;53(6):699-723
17904591
Neuron. 2001 Jul 19;31(1):131-41
11498056
Nature. 1996 Oct 24;383(6602):713-6
8878480
Amino Acids. 2000;19(1):133-49
11026482
Eur J Neurosci. 2000 Jun;12(6):1941-8
10886335
Trends Pharmacol Sci. 1990 Sep;11(9):379-87
2238094
Curr Alzheimer Res. 2005 Apr;2(2):155-65
15974913
J Neurochem. 1999 Aug;73(2):548-56
10428050
J Pharmacol Exp Ther. 2006 Jun;317(3):973-9
16527903
Proc Natl Acad Sci U S A. 1988 Feb;85(4):1307-11
2448800
Neuropharmacology. 2007 Sep;53(3):415-20
17632186
Surv Ophthalmol. 2001 May;45 Suppl 3:S284-9; discussion S295-6
11377450
Neuropharmacology. 1995 Oct;34(10):1239-58
8570022